Loading MindReaderBio...
PhD/MD Science + Investor Acumen
Bridging the gap between clinical data and market-beating returns by providing specialized research and strategic investment across listed biotech, general equities, and private equity.
The Science + Finance Edge
Biotech investing requires a complete 360° view. We bridge the gap between science and finance.
Scientific Excellence
PhD/MD-Level Analysis
- Deep dive into Mode of action
- Trial design evaluation
- Statistical rigor check
- Competitive landscape
Investor Expertise
Proven Financial Success
- >90% portfolio returns 2025
- 36% average 2020-2026
- Risk-adjusted sizing
- Entry/exit strategies
Who This Is For
We are not for everyone. We build high-conviction portfolios for serious investors.
Ideal for Investors Who:
- Have experience investing but want biotech-specific expertise
- Understand that biotech is high-risk, high-reward
- Want to understand the SCIENCE behind the stocks
- Seek an edge beyond what CNBC or Bloomberg provides
- Value independent research (no Wall Street conflicts)
- Are willing to hold positions through volatility
NOT Suitable For:
- Day traders seeking quick flips
- Risk-averse investors (biotech is inherently volatile)
- Those expecting guaranteed returns
- Investors unwilling to do additional due diligence
- People looking for 'hot tips' without understanding the thesis
- Short-term thinking (weeks/months)
Performance Metrics
Results that
Outperform the Market.
We are currently in beta and are providing a transparent paper trail of our investments, allowing users to track our decisions and performance over time.
>90%
Portfolio Return
Our 2025 integrated portfolio, combining high-conviction biotech and general equities, significantly outperformed both the Nasdaq Composite and the S&P 500.
Total Transparency Commitment
We publish every recommendation, entry price, and exit in real-time. No hiding behind vague "watchlists".
